Exhibit 99.2
LecTec Corporation
5610 Lincoln Drive
Edina, Minnesota 55436
Contact: Bill Johnson, Controller (952-933-2291 X24)
LecTec Corporation Engages Patent Litigation Counsel
June 16, 2008 — Edina, MN — LecTec Corporation (OTCBB: LECT) announced today that it has engaged
the law firm of Rader, Fishman & Grauer PLLC to represent it in connection with its patent
portfolio. Rader, Fishman & Grauer ranks as one of the top patent litigation firms in the US and
has represented clients in more than three hundred federal court cases since 1996. Rader Fishman
is recognized as a “go to” law firm by companies engaged in patent litigation. LecTec will be
working with R. Terrance Rader, considered one of the country’s top patent litigators with over
three decades of experience, along with Thomas E. Bejin and Glenn Forbis who each have in excess of
fifteen years of patent trial experience. LecTec looks forward to working with the Rader Fishman
firm. .
About LecTec Corporation
LecTec Corporation is an intellectual property licensing and holding company. The Company’s primary
focus is to derive royalty and other income from patents that the Company owns based on its
advanced skin interface technologies. The Company was an innovator in hydrogel-based topical
delivery of therapeutic over-the-counter medications, which provide alternatives to topical creams
and ointments. A hydrogel is a gel-like material having an affinity for water and similar
compounds. These gels are ideal for delivering medication onto the skin. The Company holds multiple
domestic and international patents on its hydrogel technology.
Cautionary Statements
This press release contains forward-looking statements concerning possible or anticipated future
results of operations or business developments which are typically preceded by the words
“believes,” “wants,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar
expressions. Such forward-looking statements are subject to risks and uncertainties, which could
cause results or developments to differ materially from those, indicated in the forward-looking
statements. Such risks and uncertainties include, but are not limited to, the Company’s dependence
on royalty payments from Novartis Consumer Health, Inc. (“Novartis”), which recently began selling
an adult vapor patch licensed by the Company, the Company’s dependence on key personnel and Board
of Director members, the success or failure of any attempt by the Company to protect or enforce its
patents and territories of coverage, the issuance of new accounting pronouncements, the
availability of opportunities for licensing agreements related to patents that the Company holds,
limitations on market expansion opportunities, and other risks and uncertainties detailed from time
to time in the Company’s filings with the Securities and Exchange Commission, and particularly as
described in the “Cautionary Statements” filed as Exhibit 99.01 to our Form 10-KSB for the year
ended December 31, 2007.